Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for nivolumab
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nivolumab or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on nivolumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Nivolumab (Opdivo) - melanoma 1 Published 10 December 2018 1 SMC2112 nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®) Bristol-Myers Squibb Pharmaceuticals Limited 9 November 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission nivolumab (Opdivo ® ) is accepted for use (...) within NHSScotland. Indication under review: As monotherapy for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. Adjuvant treatment with nivolumab improved recurrence free survival compared with another immunotherapy in adults with melanoma with involvement of lymph nodes or metastatic disease who had undergone complete resection. SMC advice takes account of the benefit of Patient Access Schemes (PAS
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial 30361170 2018 12 03 1474-5488 19 11 2018 Nov The Lancet. Oncology Lancet Oncol. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. 1480-1492 S1470-2045(18)30700-9 10.1016/S1470-2045(18)30700-9 Previously reported (...) results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study. In this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma
Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma 30253076 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. 1522-1524 10.1111/1759-7714.12872 Nivolumab, an anti-PD-1 antibody, has been shown to be effective in many cancers, such as malignant melanoma and lung cancer; however, nivolumab therapy can result (...) in pseudoprogression. Diffuse alveolar hemorrhage (DAH) is persistent or recurrent pulmonary hemorrhage as a result of drugs, autoimmune diseases, or infections. DAH with pseudoprogression during nivolumab administration has rarely been reported. Herein, we describe our experience with one such case. A 41-year-old woman exhibited bloody sputum and ground glass opacities in the lungs along with tumor growth during nivolumab therapy for multiple lung metastases of malignant melanoma. We diagnosed DAH
Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis 30152594 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. 1519-1521 10.1111/1759-7714.12853 The efficacy and safety of immune-checkpoint inhibitors in non-small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62-year (...) -old man with multiple pleural tumors and carcinomatous pleurisy. High-resolution computed tomography indicated usual interstitial pneumonia, and a respiratory function test revealed a restrictive disorder and decreased diffusion capacity. He was diagnosed with lung adenocarcinoma and IPF. After failure of initial chemotherapy, he was treated with nivolumab and achieved a complete response without any sign of exacerbation of IPF. The response to nivolumab has persisted for > 1 year
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. BACKGROUND: Brain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies of nivolumab combined with ipilimumab in metastatic melanoma have excluded patients with untreated brain metastases. We evaluated the efficacy and safety of nivolumab plus ipilimumab in patients with melanoma who had untreated brain metastases. METHODS: In this open-label (...) , multicenter, phase 2 study, patients with metastatic melanoma and at least one measurable, nonirradiated brain metastasis (tumor diameter, 0.5 to 3 cm) and no neurologic symptoms received nivolumab (1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for up to four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks until progression or unacceptable toxic effects. The primary end point was the rate of intracranial clinical benefit, defined as the percentage
Presence of few PDâ€1â€expressing tumorâ€infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for nonâ€small cell lung cancer: An exploratory case series 30126069 2018 11 14 1759-7714 9 10 2018 Oct Thoracic cancer Thorac Cancer Presence of few PD-1-expressing tumor-infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non-small cell lung cancer: An exploratory (...) case series. 1305-1311 10.1111/1759-7714.12844 The combination of PD-1 inhibitors and cytotoxic drugs is reported to enhance anti-tumor activity in non-small cell lung cancer; however, the underlying synergistic mechanisms remain uncertain. This retrospective case series was designed to investigate objective response and survival rates of salvage chemotherapy following nivolumab and explore the immunohistochemical profiles of tumor-infiltrating immune cells. The medical records of 37 patients
Neutrophilâ€toâ€lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated nonâ€smallâ€cell lung cancer 30126063 2018 11 14 1759-7714 9 10 2018 Oct Thoracic cancer Thorac Cancer Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer. 1291-1299 10.1111/1759-7714.12838 Although phase III trials have shown improved overall and progression-free (...) survival (PFS) using nivolumab compared to docetaxel in patients with non-small-cell lung cancer, the progressive disease ratio of nivolumab is higher than docetaxel. Furthermore, nonconventional response patterns of nivolumab make it difficult to determine the time point for nivolumab discontinuation. Therefore, a method to detect non-responders to nivolumab at an early time point is crucial. This retrospective study was conducted to identify immunological and nutritional markers, including neutrophil
Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab 30072374 2018 11 14 2473-9537 2 15 2018 Aug 14 Blood advances Blood Adv Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab. 1865-1868 10.1182/bloodadvances.2018019000 Hasanov Merve M http://orcid.org/0000-0002-6102-4917 Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX; and. Konoplev Sergej N SN Department
Nivolumab Top results for nivolumab - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for nivolumab The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines
Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity 30094065 2018 11 14 2059-7029 3 5 2018 ESMO open ESMO Open Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. e000332 10.1136/esmoopen-2018-000332 Nivolumab is used at 3 mg/kg or fixed doses of 240 mg every 2 weeks. There was no dose-response/toxicity relationship of nivolumab. This study evaluated the efficacy of low-dose (...) nivolumab as an alternative to the financial toxicity of standard-dose nivolumab in treatment of non-small cell lung cancer (NSCLC). Outcomes of patients with NSCLC treated with nivolumab as a routine practice at two tertiary hospitals in Korea were retrospectively analysed. Patients who could not afford standard nivolumab treatment received low-dose nivolumab (20 or 100 mg fixed dose every 3 weeks). Others received standard dose of 3 mg/kg every 2 weeks. Progression-free survival (PFS) and overall
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer). BACKGROUND: Hodgkin's lymphoma (HL) is a cancer of the lymphatic system, and involves the lymph nodes, spleen and other organs such as the liver, lung, bone or bone marrow, depending on the tumour stage. With cure rates of up to 90%, HL is one of the most curable cancers worldwide. Approximately 10% of people with HL will be refractory to initial treatment or will relapse; this is more common (...) activity in a wide range of malignancies. Nivolumab is an anti-(PD)-1 monoclonal antibody and currently approved by the US Food and Drug Administration (FDA) for the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and, since 2016, for classical Hodgkin's lymphoma (cHL) after treatment with ASCT and brentuximab vedotin. OBJECTIVES: To assess the benefits and harms of nivolumab in adults with HL (irrespective of stage of disease). SEARCH METHODS: We searched CENTRAL, MEDLINE
Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24 1 Translation of addendum A17-54 Nivolumab (Plattenepithelkarzinom des Kopf-Hals-Bereichs) – Addendum zum Auftrag A17-24 (Version 1.0; Status: 25 October 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 25 October 2017 1.0 Commission: A17-54 Version: Status (...) : IQWiG Reports – Commission No. A17-54 Nivolumab (squamous cell carcinoma of the head and neck) – Addendum to Commission A17-24 1 Addendum A17-54 Version 1.0 Nivolumab – Addendum to Commission A17-24 25 October 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (squamous cell carcinoma of the head and neck) – Addendum to Commission A17-24 Commissioning agency: Federal Joint Committee
Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy 30202808 2018 11 14 2452-1094 3 3 2018 Jul-Sep Advances in radiation oncology Adv Radiat Oncol Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy. 399-404 10.1016/j.adro.2018.04.015 Radiation therapy (RT) and nivolumab are standard therapies for a wide range of advanced and metastatic cancers, yet little is known about the toxicity profile of their combined treatment (...) . The rate of grade ≥3 toxicities from nivolumab monotherapy and radiation-only palliative treatments has been reported at 10% to 18% and 0% to 26%, respectively. We reviewed our experience to assess the acute toxicity profile of concurrent RT-nivolumab. A retrospective review of all consecutive patients from January 2015 to May 2017 who received concurrent RT-nivolumab was conducted at 4 separate centers. Concurrent RT-nivolumab was defined as RT completed between 3 days prior to initial nivolumab
Efficacy and safety of nivolumab in nonâ€small cell lung cancer with preexisting interstitial lung disease 29782069 2018 11 14 1759-7714 9 7 2018 Jul Thoracic cancer Thorac Cancer Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. 847-855 10.1111/1759-7714.12759 The risk of developing lung cancer is high in patients with interstitial lung disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are used (...) for the treatment of non-small cell lung cancer (NSCLC) in clinical practice; however, in patients with preexisting ILD, the risk of ICI-related pneumonitis is unknown. We evaluated the efficacy and lung toxicity of nivolumab in patients with NSCLC and ILD. We retrospectively reviewed the medical records of 216 NSCLC patients who had received nivolumab therapy. The existence of ILD in these patients was determined by lung computed tomography findings; 26 patients had ILD. We evaluated the efficacy of nivolumab
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer 29692997 2018 11 14 2312-0541 4 2 2018 Apr ERJ open research ERJ Open Res Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer. 00120-2017 10.1183/23120541.00120-2017 Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation (...) , but better overall survival (OS), suggesting regained efficacy of treatments given thereafter. We aimed to evaluate the efficacy of nivolumab and of next treatment received after nivolumab progression in patients with advanced NSCLC. Our multicentre retrospective study included all patients receiving nivolumab between January and December 2015. The primary end-point was progression-free survival (PFS) of treatment given after nivolumab. The 303 patients had the following characteristics: median age 63
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. Background Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden (≥10 (...) mutations per megabase). Methods We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy. Those with a level of tumor programmed death ligand 1 (PD-L1) expression of at least 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab monotherapy, or chemotherapy; those with a tumor PD-L1 expression level of less than 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab plus
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. Background Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. Methods We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram (...) ) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level,0.04), objective response rate (alpha level,0.001), and progression-free survival (alpha level,0.009) among patients with intermediate or poor prognostic risk. Results A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546